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Background: Electronic monitoring devices (EMDs) are regarded as the “gold standard” for 
assessing medication adherence in research. Although EMD data provide rich longitudinal 
information, they are typically not used to their maximum potential. Instead, EMD data are 
usually combined into summary measures, which lack sufficient detail for describing complex 
medication-taking patterns. This paper uses recently developed methods for analyzing EMD 
data that capitalize more fully on their richness.
Methods: Recently developed adaptive statistical modeling methods were used to analyze 
EMD data collected with medication event monitoring system (MEMS™) caps in a clinical 
trial testing the effects of motivational interviewing on adherence to antihypertensive medica-
tions in a cohort of hypertensive African-Americans followed for 12 months in primary care 
practices. This was a secondary analysis of EMD data for 141 of the 190 patients from this 
study for whom MEMS data were available.
Results: Nonlinear adherence patterns for 141 patients were generated, clustered into seven 
adherence types, categorized into acceptable (for example, high or improving) versus unac-
ceptable (for example, low or deteriorating) adherence, and related to adherence self-efficacy 
and blood pressure. Mean adherence self-efficacy was higher across all time points for patients 
with acceptable adherence in the intervention group than for other patients. By 12 months, there 
was a greater drop in mean post-baseline blood pressure for patients in the intervention group, 
with higher baseline blood pressure values than those in the usual care group.
Conclusion: Adaptive statistical modeling methods can provide novel insights into patients’ 
medication-taking behavior, which can inform development of innovative approaches for tailored 
interventions to improve medication adherence.
Keywords: adaptive statistical modeling, hypertension, medication adherence, Medication 
Event Monitoring System
Introduction
An increasingly common approach for measuring medication adherence is the elec-
tronic monitoring device (EMD), often the Medication Event Monitoring System 
(MEMS™) cap (AARDEX Group Ltd, Sion, Switzerland). EMDs have been used to 
monitor adherence with antihypertensive medications1–7 and with a variety of other 
medications. They provide rich information on the timing of events, but most analyses 
of EMD data focus on simple summary adherence measures, such as percent prescribed 
doses taken and percent prescribed doses taken at the correct time interval.8 These 
summary adherence measures do not use EMD data to their maximum potential, in 
part because they are based on an implicit assumption of constant adherence over time, 
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which often does not hold. In addition, summary adherence 
measures do not provide sufficient detail to describe the 
complex patterns of medication-taking behavior. In contrast, 
Düsing et al and Vrijens et al modeled daily adherence with 
logistic regression methods adjusted for correlation using 
generalized estimating equations.2,7
The adaptive statistical modeling (ASM) approach is 
intermediate between the summary measure approach and 
modeling of daily adherence.9 ASM analyses are based on 
counts and rates of EMD events (for example, MEMS cap 
openings) within distinct time periods during a patient’s 
participation in a study. These counts/rates are modeled 
using Poisson regression models based on multiple power 
transforms of time with arbitrary real-valued powers. The 
transforms and their powers are generated through an 
  adaptive (ie, adapted to the data) process based on a   heuristic, 
rule-based search, and these models provide curves represent-
ing individual patient adherence patterns that are clustered 
into adherence types. Aloia et al used a similar approach, 
  analyzing EMD adherence to continuous positive airway 
pressure treatment for patients with obstructive sleep apnea 
using time series models and classification of patient adher-
ence based on parameter estimates for those models.10 ASM 
methods have been used to provide a variety of insights into 
adherence using EMD data, for example, establishing the 
efficacy of interventions, identifying signature adherence 
types, and matching patients to interventions.11 However, 
ASM methods have currently only been applied to EMD 
adherence data for antiretroviral medications.12,13
This paper reports on the use of ASM methods to analyze 
EMD data on adherence to antihypertensive medications in 
a cohort of African-American patients with hypertension. 
Findings from reported analyses provide novel insights into 
adherence for these patients. These findings are of impor-
tance with regard to medication adherence in the particular 
case of hypertensive African-American patients, and sug-
gest the need for similar analyses in general electronically 
monitored adherence settings.
Materials and methods
Motivational interviewing study
The motivational interviewing (MINT) study was a 
r  andomized, controlled trial designed to compare the effects of 
MINT and usual care on medication adherence in h  ypertensive 
African-Americans followed in two primary care practices 
in New York City.4,14 The study methods have been reported 
elsewhere.4 Briefly, patients were approached to participate 
in the study during regular clinic visits. All patients were 
provided with written informed consent forms approved by the 
institutional review board of Weill Cornell Medical College 
and Columbia University Medical Center. After the patients 
consented to participate in the study, research   assistants 
conducted baseline interviews, gave the patients a pill bottle 
with a MEMS cap to record openings, and instructed them 
on how to use it. When patients were prescribed multiple 
antihypertensive medications, their providers were asked to 
choose a medication taken once daily to be placed in the bottle. 
Following the baseline assessment, patients were randomly 
assigned to either the MINT or usual care group. Follow-up 
assessments were carried out at 3-month intervals for a period 
of one year (a total of four post-baseline visits), during which 
patient medication adherence data were downloaded from 
their MEMS caps.
Outcomes of MiNT study
The primary outcome was the percent prescribed doses taken, 
as assessed by MEMS caps. Poor adherence was defined as 
taking less than 80% of the prescribed doses. Secondary 
outcomes included within-patient changes in adherence 
self-efficacy, systolic blood pressure, and diastolic blood 
pressure from baseline to 12 months. Patient electronic medi-
cal records were reviewed for systolic and diastolic blood 
pressure readings at each study visit. The within-patient 
change in systolic/diastolic blood pressure was computed 
as the difference in systolic/diastolic blood pressure between 
the baseline and 12-month readings. Adherence self-efficacy 
was measured using a 25-item Medication Adherence Self-
Efficacy Scale developed to assess patients’ confidence in 
taking their antihypertensive medications under a variety 
of situations that might pose difficulties for them.15 This 
scale used a four-point Likert-type response format from 
1 (not at all sure) to 4 (extremely sure). Scores for each 
item were summed and averaged so that the range of pos-
sible scores was 1 to 4, with higher scores reflecting greater 
self-efficacy. Cronbach’s alphas ranged from 0.88 to 0.91 
over 0 to 12 months. Within-patient changes in adherence 
self-efficacy from baseline to 12 months were computed as 
differences in adherence self-efficacy scores between these 
two time points. Adherence self-efficacy, and systolic and 
diastolic blood pressure data were collected at baseline and 
at months 3, 6, 9, and 12. Using an intent-to-treat analysis, 
it was found that the MINT group had better medication 
adherence than the usual care group.14
This paper reports on secondary analyses of EMD 
data and longitudinal outcomes from the MINT study 
using ASM methods. The analyses serve as examples of 
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the   application of ASM methods and their usefulness for 
  modeling medication adherence and assessing their impact 
on patient outcomes.
Description of ASM methods
ASM methods were originally formulated for Poisson regres-
sion modeling of mean adherence.9 They were then extended 
to identify adherence types using adaptive clustering,12 to 
model repeated-measures data adaptively, accounting for 
within-patient correlation,16 and to model adherence vari-
ability adaptively, along with mean adherence over time.13 
An overview of these ASM methods used is provided below. 
Reported ASM analyses were conducted in SAS software 
(version 9.2; SAS Institute Inc, Cary, NC) using SAS macros 
available from the corresponding author.
In ASM, each patient’s EMD data are grouped into 
  distinct, nonoverlapping time intervals. One hundred equal-
sized intervals are used as long as the length of these inter-
vals is at least 3 days. Otherwise, the number of intervals is 
reduced so that the interval length is at least 3 days. Counts 
of numbers of EMD events are computed for each of the 
intervals, as well as associated EMD rates per unit time. 
The counts are modeled using Poisson regression with the 
canonical log link function and the appropriate offset vari-
able to convert from a model for the counts to a model for 
associated rates. Models are generated for mean adherence 
in terms of expected values for rates as nonlinear functions 
of time using one or more power transforms of time with 
real-valued powers; thus, these are called fractional poly-
nomial models.17
For standard Poisson regression models, variances equal 
the means. An extended quasi-likelihood approach18 is used 
with ASM methods to include dispersions that generalize the 
variances of linear regression models, thereby providing a 
measure of adherence variability. Dispersions are also mod-
eled with fractional polynomials as nonlinear functions of 
time based on power transforms of time, not necessarily the 
same as those used for modeling mean adherence.
To visualize an individual patient’s adherence pattern, 
observed adherence rates are plotted along with estimates of 
the mean adherence curve and estimates of unit error bands 
(ie, ±1 standard deviation) around that curve (see Figure 2 
for examples). A measure is also computed of percent con-
sistency of observed adherence rates with the prescribed 
adherence rate. This is computed as the percent of change 
from the prescribed rate corresponding to the associated 
constant unit error bands, assuming mean adherence at the 
prescribed rate and constant dispersion.
Power transforms for these models are adaptively selected 
using rule-based search techniques (for details, see Knafl 
et al13). A two-phase search process is used. First, the model is 
systematically expanded from the constant model by adding 
power transforms of primary predictors (for example, time for 
EMD data analyses). Next, the expanded model is contracted 
to a parsimonious model by removing extraneous transforms, 
if any, and adjusting the remaining power transforms with 
each removal. Models are evaluated with likelihood cross-
validation scores. Larger likelihood cross-validation scores 
indicate better models more consistent with the data.
The steps in the process are controlled by rules based 
on tolerance parameters indicating how much a penalty in 
reduced likelihood cross-validation scores can be tolerated at 
each phase to continue processing. For example, the expan-
sion (or contraction) phase stops when the percent decrease 
in likelihood cross-validation scores for the next model to 
add (or remove) exceeds the setting of the associated toler-
ance parameter. Likelihood cross-validation ratio tests based 
on the χ2 distribution, analogous to likelihood ratio tests,19,20 
are used to determine tolerance parameter settings that con-
trol the search. Likelihood cross-validation ratio tests can 
also be used to assess whether likelihood cross-validation 
scores for two models differ substantially (for an example, 
see Knafl et al13), but these kinds of tests are not reported 
in this paper.
This search process can be used to generate not only 
adaptive Poisson regression models for count/rate outcomes, 
but also adaptive regression models for continuous outcomes 
and adaptive logistic regression models for dichotomous 
outcomes. The process can also be used to generate adap-
tive repeated-measures models for longitudinal patient 
outcomes.16
Individual-patient adherence patterns for estimated 
mean adherence and adherence variability at proportion-
ally spaced times during patients’ study participation are 
clustered into adherence types (for example high, low, 
deteriorating, improving). Means for available longitudinal 
outcomes are adaptively modeled in terms of time, treatment 
group, adherence type, and associated interactions, while 
accounting for temporal correlation using adaptive repeated-
measures methods.16 Two possible correlation structures are 
considered: the standard repeated-measures approach with 
constant correlations for different times and the more com-
mon longitudinal approach with order 1 spatial autoregres-
sive correlations, which weaken the farther apart outcomes 
are in time. Variances are treated as constant over time as in 
standard repeated-measures analyses.
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Results
Baseline characteristics of MiNT  
study patients
A total of 190 patients (equally randomized to each group) 
participated in the MINT study (Table 1). The majority of the 
patients were women (88.4%), were 40–69 years old (77.9%), 
had a high school degree or less (67.9%), were unmarried 
(82.6%), were unemployed (77.9%), had a reported annual 
income below $20,000 (64.2%), were on Medicaid (73.7%), 
had uncontrolled baseline blood pressure (68.9%), and/or 
had high baseline adherence self-efficacy of at least 3.5 out 
of 4 (55.3%).
MEMS data were available for 141 (74.2%) of the 
participants, with 70 (49.6%) from the MINT group 
(Figure 1). Missing MEMS data was a consequence of a 
variety of factors, including lost or malfunctioning caps 
as well as patients not returning their MEMS caps for 
downloading at follow-up assessments. Patients with and 
without MEMS data did not differ significantly on any of 
the baseline characteristics (using χ2 or Fisher’s exact test 
as   appropriate). Hence, results for patients with MEMS 
data can be reasonably considered to be representative of 
results for the total sample.
individual-patient adherence patterns
Observed adherence rates were modeled for each of the 
141 patients with available MEMS data in terms of mean 
adherence and adherence variability over the 12-month 
study period. Results are plotted in Figure 2. These plots are 
similar to the chronology plots of Vrijens et al7 in depicting 
observed adherence rates (plotted as circles) over time and 
their variability, but they also provide fitted mean adherence 
curves (the middle curve of the plots) and adherence vari-
ability curves (the outer two curves of the plots) not addressed 
in chronology plots.
For patient 1, mean adherence was very high, at almost 
exactly the prescribed rate of one dose per day throughout 
the patient’s participation period, and adherence variability 
was reasonably low although somewhat higher early in study 
participation. The observed adherence was 90.9% consistent 
with adherence at the prescribed rate. Patient 2 had high mean 
adherence, below but not too much below the prescribed rate 
and moderate adherence variability, being 48.1% consistent 
with adherence at the prescribed rate. Patient 3 had a convex 
mean adherence pattern, deteriorating somewhat early on but 
then improving to high by the end of study participation along 
with moderate to low adherence variability, for a percent 
consistency of 15.2%.
Table 1 Baseline characteristics of patients in the MiNT study
Characteristic n  %
Treatment group
  Usual care 95 50
  MiNT 95 50
Gender
  Female 168 88.4
  Male 22 11.6
Age
  ,40 22 11.6
  40–69 148 77.9
  $70 20 10.5
Education
  Elementary school 44 23.2
  High school 85 44.7
  Some college or better 61 32.1
Marital status
  Single 84 44.2
  Married 33 17.4
  Separated or divorced 58 30.5
  Widowed 15 7.9
Employment status
  Full time 29 15.3
  Part time 13 6.8
  retired 20 10.5
  Not working 103 54.2
  On disability 25 13.2
Annual income level
  Under $20,000 122 64.2
  $20,000 or more 39 15.3
  Unknown 29 20.5
insurance status
  insurance plan or HMO 13 6.8
  Medicare 22 11.6
  Medicaid 140 73.7
  Self insurance 15 7.9
Baseline SBP
  Controlled (SBP , 140) 80 42.1
  Uncontrolled (SBP $ 140) 110 57.9
Baseline DBP
  Controlled (DBP , 90) 94 52.1
  Uncontrolled (DBP $ 90) 91 47.9
Baseline BP
  Controlled (SBP , 130 and DBP , 90) 59 31.1
  Uncontrolled (SBP $ 140 or DBP $ 90) 131 68.9
Baseline adherence self-efficacy
  ,3.5 85 44.7
  $3.5 105 55.3
MEMS data
  None available 49 25.8
  Some available 141 74.2
Note: Out of 190 African-American patients. 
Abbreviations: BP, blood pressure; DBP, diastolic BP; SBP, systolic BP; HMO, 
Health  Maintenance  Organization;  MEMS,  Medication  Event  Monitoring  System; 
MiNT, motivational interviewing.
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Current study 
141 patients  
with MEMS data 
Figure 1 Patients from the parent motivational interviewing study and the current study.
Patients 1, 2, and 3 had either very high, high, or 
improving and thus acceptable adherence patterns, respec-
tively. Other patients had deteriorating or very low and 
thus unacceptable adherence patterns. Patient 4 had mean 
adherence that deteriorated from very high to low over time, 
along with high to moderate adherence variability, for a 
percent consistency of 0.1%. Patient 5 had mean adherence 
that gradually deteriorated from moderate to low over time 
and adherence variability that decreased from moderate to 
low, for a percent consistency of 0.1%. Patient 6 had mean 
adherence that deteriorated from high to zero early on and 
adherence variability that decreased from low to zero, for a 
percent consistency of 0.1%. Patient 7 had very low mean 
adherence over time and also very low adherence variability, 
for a percent consistency of 0.1%.
Categorization of adherence  
patterns into types
Patients with MEMS data were clustered into groups based on 
their individual adherence patterns. The clusters were based 
on estimated mean adherence and adherence   variability, 
computed at 5%, 10%, …, and 95% of time during study 
participation, for each of the 141 patients. For example, the 
study participation by patient 1 was 267 days, and so mean 
adherence and adherence variability estimates for this patient 
were computed at 13.4 (5% of 267) days, 26.7 (10% of 267) 
days, …, and 253.7 (95% of 267) days.
Likelihood cross-validation scores were computed for 
multivariate normal mixture models,21 with means and vari-
ances treated as different across clusters, and with a common 
unstructured correlation matrix for all clusters to limit the 
number of parameters. Clusters were restricted to include at 
least 5% of the patients to avoid sparse clusters. The cluster-
ing approach with the best likelihood cross-validation score 
generated seven clusters using Ward’s method based on 
standard Euclidean distance.22 Adherence types correspond-
ing to these clusters are described in Table 2. Patients 1 to 7 
were chosen as representative of clusters 1 to 7. Averages of 
mean adherence and of adherence variability for patients in 
each cluster, as plotted in Figure 3, were used to determine 
Table 2 adherence type descriptions. These were similar to, 
but not always exactly the same as, mean adherence and 
adherence variability for patients 1 to 7.
Cluster 1 corresponded to very high adherence, cluster 
2 to high adherence, and cluster 3 to improving adherence. 
Thus, these three clusters represented acceptable adher-
ence (ie, relatively high or improving). Clusters 4 to 6 
corresponded to deteriorating adherence, while Cluster 7 
corresponded to very low adherence. Thus, clusters 4 to 7 
represented unacceptable adherence. These categorizations 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
211
Electronically monitored adherence to antihypertensivesPatient Preference and Adherence 2012:6
0
0.5
1
1.5
2
06 01 20 1802 40 300
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 1 – 90.9% consistency
0
0.5
1
1.5
2
06 01 20 1802 40
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 2 – 48.1% consistency
0
0.5
1
1.5
2
06 01 20 1802 40 300
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 3 – 15.2% consistency
0
0.5
1
1.5
2
06 01 20 180 2403 00 360 420 480 540
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 4 – 0.1% consistency
0
0.5
1
1.5
2
06 01 20 1802 40 3003 60
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 5 – 0.1% consistency
0
0.5
1
1.5
2
06 01 20 1802 40 300 3604 20 480
O
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 6 – 0.1% consistency
0
0.5
1
1.5
2
06 0 120 180 240 3003 60  420
o
p
e
n
i
n
g
s
 
p
e
r
 
d
a
y
Cumulative days within study participation
Patient 7 – 0.1% consistency
Figure 2 Example individual-patient adherence patterns.
of adherence were supported by decreasing average   percent 
consistency and percent prescribed doses taken with 
increasing cluster indexes (Table 2). Note that cluster 5 
  corresponded to what Vrijens et al7 refer to as poor quality 
of execution, while clusters 4, 6, and 7 represented what 
they describe as short persistence (ie, disengagement from 
the dosing regimen). Note also that adherence was measured 
over the whole study period, including during periods of 
nonpersistence.
Patients with acceptable adherence were significantly 
[(χ2(1) = 76.05; P , 0.001] more likely to have a high 
percentage of prescribed doses taken (defined as at least 
80% prescribed doses taken as in the parent study). However, 
only 70.8% of the patients with acceptable adherence as 
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Figure 3 Average adherence patterns for adherence clusters.
Table 2 Adherence clusters
Cluster n % Adherence types Average %  
consistency
Average % prescribed   
doses taken Mean adherence Adherence variability
1 19 13.5 Very high Low 80.8 97.2
2 37 26.2 High Moderate 50.6 84.9
3 9 6.4 improving Low to moderate 14.1 55.1
4 10 7.1 Deteriorating from  
very high
Deteriorating from  
very high
1.1 51.0
5 18 12.8 Deteriorating from  
moderate gradually
Deteriorating from  
moderate gradually
7.7 42.3
6 26 18.4 Deteriorating from 
moderate early on
Deteriorating from  
moderate early on
0.1 14.5
7 22 15.6 Very low Very low 0.1 5.8
Total 141 100
determined by ASM also had high percent prescribed 
doses taken. This suggests that the categorization into 
  acceptable and unacceptable adherence based on ASM d  iffers 
distinctly from the commonly used categorization based 
on percent prescribed doses taken scores,   underscoring the 
potential problems with assuming constant adherence over 
time.
The important study outcome of having uncontrolled blood 
pressure (ie, either systolic blood pressure $ 140 mmHg or 
diastolic blood pressure $ 90 mmHg) at 12 months did not 
depend on having a high percentage of prescribed doses 
taken $80% [χ2(1) = 0.24; P = 0.627]. However, the chance 
of having uncontrolled blood pressure at 12 months was 
significantly higher for patients with deteriorating adherence 
than for other patients [χ2(1) = 7.59; P = 0.006].
Adherence type effects on means for patient outcomes 
can be assessed using all seven adherence types or other 
categorizations of adherence, including very high versus not, 
either very high or high versus not, and acceptable (ie, very 
high, high, or improving) versus unacceptable. However, 
computing times can be quite long. For that reason, analyses 
of mean patient outcomes (adherence self-efficacy, systolic 
and diastolic blood pressure) were restricted to adherence 
categorized as acceptable or unacceptable.
Adaptive analysis of adherence  
self-efficacy
There were 687 adherence self-efficacy measurements for the 
141 patients with available MEMS data over five possible 
time points, for an average of 4.9 measurements per patient. 
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An adaptive analysis was conducted to determine the effects 
of adherence (acceptable versus unacceptable), treatment 
group (MINT versus usual care), time, and their interactions 
on mean adherence self-efficacy. Autoregressive correlations 
were used because these generated better likelihood cross-
validation scores than constant correlations.
The model generated for adherence self-efficacy depended 
on time, treatment group, and adherence type (Figure 4). 
There were two mean adherence self-efficacy patterns, one 
for patients in the MINT group with acceptable adherence 
and one for all other patients. Mean adherence self-efficacy 
started at the same baseline level and tended to increase over 
time, but post-baseline mean adherence self-efficacy was 
higher at all times for patients in the MINT group with more 
acceptable adherence than for other patients. These results 
suggest that there were MINT group improvements in mean 
adherence self-efficacy, but only for MINT patients with 
acceptable adherence, not for all patients in the MINT group. 
The estimated standard deviation for adherence self-efficacy 
was 0.41, while estimated correlations decreased from 0.57 
at 3 months apart to 0.11 at 12 months apart.
Adaptive analyses of systolic  
blood pressure
There were 568 systolic blood pressure measurements for 
141 patients with available MEMS data over five possible 
time points, for an average of 4.0 measurements per patient. 
An ASM model was first generated for systolic blood pressure 
over these five time points. The results indicated that mean 
systolic blood pressure did not change significantly according 
to treatment group (MINT versus usual care) or adherence 
type (acceptable versus unacceptable). However, this could 
have been a consequence of not adjusting post-baseline 
  systolic blood pressure values for baseline values, and so ASM 
analyses were also conducted to address this issue.
There were 427 post-baseline systolic blood pressure 
measurements for 137 patients with available MEMS data 
(four patients had only baseline systolic blood pressure 
  measurements) over four possible post-baseline time points, 
for an average of 3.3 measurements per patient. ASM 
analyses used constant correlations because these generated 
better likelihood cross-validation scores than autoregressive 
correlations.
The ASM-generated model was based on baseline systolic 
blood pressure, time, and treatment group, but not on adher-
ence type (Figure 5). For patients with low baseline systolic 
blood pressure, mean systolic blood pressure was essentially 
the same for both treatment groups and at all times. For 
patients with high baseline systolic blood pressure, mean 
post-baseline systolic blood pressure was lower for partici-
pants in the MINT group than those in the usual care group, 
with larger differences for increased baseline systolic blood 
pressures and at later times. The estimated constant standard 
deviation for post-baseline systolic blood pressure was 15.6. 
The estimated constant correlation was 0.29.
Adaptive analyses of diastolic  
blood pressure
There were 568 diastolic blood pressure measurements for 
141 patients with available MEMS data over five possible 
time points, for an average of 4.0 measurements per patient. 
As for diastolic blood pressure, analyses over all five time 
points identified no treatment group or adherence type 
effects, and thus post-baseline diastolic blood pressure was 
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Figure 4 Mean adherence self-efficacy over time and by combinations of adherence type and treatment group. 
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Abbreviations: MiNT, motivational interviewing; UC, usual care.
analyzed controlling for baseline values. There were 427 
post-baseline diastolic blood pressure measurements for 
137 patients with available MEMS data (four patients had 
only baseline systolic blood pressure measurements) over 
the four possible post-baseline time points, for an average 
of 3.3 measurements per patient. Post-baseline diastolic 
blood pressure analyses used constant correlations because 
these generated better likelihood cross-validation scores than 
autoregressive correlations.
The ASM-generated model included time, treatment 
group, and adherence type effects (Figure 6). For patients 
with high baseline diastolic blood pressure values, mean 
post-baseline diastolic blood pressure was lower for partici-
pants in the MINT group than in the usual care group; the 
values decreased over time for patients in the MINT group 
and more so for those with very high baseline diastolic blood 
pressure when they had acceptable adherence than if they had 
unacceptable adherence. The estimated constant standard 
deviation for post-baseline diastolic blood pressure was 9.8. 
The estimated constant correlation was 0.23.
Comparison with standard repeated-
measures modeling
ASM results for mean adherence self-efficacy over all five 
time points were compared with results for the full facto-
rial repeated-measures analysis of variance model in time, 
  treatment group, adherence type, and all possible interactions. 
ASM results for mean systolic/diastolic blood pressure over 
the four post-baseline time points were compared with results 
for the full factorial repeated-measures analysis of covariance 
model in time, treatment group, adherence type, and all 
possible interactions, controlling for baseline systolic/diastolic 
blood pressure. All models assumed constant correlations and 
variances as is standard for repeated-measures modeling.
The model for mean adherence self-efficacy had three 
significant terms, ie, time [F(4,530) = 16.29; P , 0.001], 
interaction of time with treatment group [F(4,530) = 4.64; 
P = 0.001], and the interaction of time with adherence type 
[F(4,530) = 3.18; P = 0.014]. The model for post-baseline 
systolic blood pressure had only one significant term, ie, base-
line systolic blood pressure [F(1,132) = 30.73; P , 0.001]. 
The model for mean diastolic blood pressure also had only 
one significant term, ie, baseline diastolic blood pressure 
[F(1,132) = 34.44; P , 0.001].
Discussion
The goal of this paper was to elucidate the usefulness of 
ASM methods for providing novel insights into patterns of 
medication-taking and a better understanding of how that 
behavior affects patient outcomes. Analyses of data from 
a completed randomized controlled trial demonstrated that 
ASM methods revealed new information about individual 
patient adherence behaviors as well as about the dependence 
of changes in study outcomes over time on patient group 
assignment ie, MINT versus usual care. More importantly, the 
adherence behaviors that were identified using ASM methods 
in this paper were not apparent from the original analyses 
based on the conventional summary measure percent pre-
scribed doses taken.14 Specifically, ASM methods were able 
to characterize patients as having several distinct a  dherence 
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behaviors (very high, high, improving, deteriorating, or 
very low adherence) that were in contrast with the usual 
dichotomy of high adherence with percent prescribed doses 
taken represented as an adherence level of $80% or not. Very 
high, high, and improving adherence could be combined to 
produce the dichotomy of acceptable versus unacceptable 
adherence, but this was much different from high percent 
prescribed doses taken or not (ie, only 70.8% of patients 
with acceptable adherence also had high percent prescribed 
doses taken). The significance of the divergent findings that 
results from these contrasting methods is best exemplified by 
analysis of the blood pressure data from this trial, including 
systolic and diastolic blood pressure. Using conventional 
summary methods, high percent prescribed doses taken had 
no effect on blood pressure control at 12 months. In contrast, 
patients with deteriorating adherence, as determined through 
ASM methods, were more likely to have uncontrolled blood 
pressure at 12 months.
Furthermore, the results suggested that the intervention 
was most beneficial to patients with higher baseline blood 
pressure levels and acceptable adherence rather than for 
all patients who were randomized to the MINT group. 
  Moreover, as expected, the MINT intervention had a posi-
tive influence on patient medication adherence self-efficacy. 
However, the effect was limited to those patients who also 
had acceptable adherence levels. In this case, the strength 
of the intervention appeared to lie in reinforcing patient 
confidence to maintain good adherence behaviors and might 
not have been suitable for addressing complex issues facing 
patients with poor adherence. Also, while the intervention 
targeted adherence behaviors, the effect of MINT on sys-
tolic blood pressure by the end of the study (12 months) 
was unrelated to adherence type. This finding attests to the 
multifactorial nature of blood pressure control. Types of 
medications and their properties and/or changes in lifestyle 
behaviors (ie, diet and exercise) were not measured in this 
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Abbreviations: MiNT, motivational interviewing; UC, usual care.
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trial, but might explain the observed reduction in systolic 
blood pressure.
Standard repeated-measures analysis of variance/ 
covariance models in time, treatment group, and adherence 
type with possible covariates can be overly complicated and 
so suggest that there are no treatment group or adherence 
type effects when in fact there are such effects (for example, 
this held for reported systolic and diastolic blood pressure 
  analyses). ASM analyses are needed to identify which effects, 
if any, are of substance and which are not. Even when standard 
repeated-measures analyses identify significant effects (as for 
reported adherence self-efficacy analyses), ASM modeling 
provides a fuller depiction of those effects. The reported 
repeated-measures analyses demonstrate that ASM methods 
can provide parsimonious descriptions of how outcomes 
change with predictors like time, baseline values, treatment 
group, adherence type, and their interactions, and so identify 
distinct effects that standard repeated-measures models can 
sometimes suggest do not exist. While ASM methods were 
used here to analyze data from a study of electronically moni-
tored adherence, they can also be used to perform adaptive 
analyses of repeated-measures data from studies addressing 
areas other than adherence.
Seven adherence types were identified in the analyses 
within three categories of relatively consistent adherence 
over time, deteriorating adherence over time, and improv-
ing adherence over time. The number of adherence types is 
likely to vary with the study under analysis, but variations on 
these three categories of adherence types can be expected to 
be identified for any type of medication. For example, Knafl 
et al13 identified 10 adherence types for subjects with human 
immunodeficiency virus (HIV) on antiretroviral medications, 
including seven relatively consistent, one deteriorating, and 
two improving adherence types. However, these adherence 
patterns were also identified in the context of a randomized 
controlled trial, so it is not clear if the same adherence pat-
terns would emerge in clinical settings.
In summary, using ASM methods, this study identified 
specific patient-related and disease-related factors (for exam-
ple, treatment group, adherence type, and baseline systolic/
diastolic blood pressure) that jointly predicted improvements 
in psychosocial outcomes (ie, adherence self-efficacy) and 
in clinical outcomes (ie, post-baseline systolic/diastolic 
blood pressure) in a sample of African-American patients 
enrolled in a motivational interviewing trial. In some cases, 
these effects were not identifiable with standard repeated-
measures methods currently used for such assessments and 
their distinct nonlinearity in none of the cases.
Limitations
The adherence data analyzed in this article were collected 
electronically using MEMS caps. Cap openings do not always 
necessarily correspond to actual medication-taking. Patients 
may have sometimes removed multiple doses at one cap 
opening in order to put them in pill boxes, in which case the 
cap openings underestimate actual adherence. On the other 
hand, patients were enrolled in a randomized controlled 
trial addressing adherence and so they may have sometimes 
opened the cap to appear adherent without actually taking 
any medications, in which case the cap openings overestimate 
actual adherence. However, positive effects on adherence 
self-efficacy and blood pressure identified in the analyses 
for acceptable compared with unacceptable adherence, as 
determined by MEMS cap openings, suggest that, for most 
patients in the MINT study, their MEMS cap data reflect 
their actual adherence quite closely.
The reported findings provide useful information for use 
in the research field of adherence to medication regimens. 
However, beneficial effects of improvements in patient 
medication-taking behaviors on blood pressure control and 
cardiovascular events remain to be determined in future 
investigations.
There are also limitations to current ASM methods that 
should be noted and these require further research. First, 
while only adaptive Poisson regression of counts/rates is 
needed for modeling EMD adherence data, ASM methods 
currently also support adaptive linear and logistic regression 
modeling of uncorrelated continuous and discrete outcomes, 
respectively. However, ASM methods currently only support 
adaptive repeated-measures modeling of correlated continu-
ous outcomes. There is a need to extend these to support 
adaptive modeling of correlated counts/rates and correlated 
discrete outcomes. Second, ASM methods currently sup-
port only two correlation structures for repeated-measures 
  analyses, which are constant as in standard repeated-measures 
modeling and order 1 autoregression. Extensions are needed 
to handle more general correlation structures, for example, 
random-effect models. Third, other methods could have 
been used. For example, latent class analysis could be used 
instead of standard clustering procedures. Delucchi et al12 
considered both these approaches for determining adher-
ence types for HIV-positive methadone patients and found 
that there was good agreement between the two alternative 
cluster assignments, but adaptive analyses were still needed 
to generate the adherence patterns they clustered. Fourth, in 
this study, variability was modeled only for adherence while 
standard constant variance models were used for analyzing 
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longitudinal outcomes. Further research is needed to address 
the impact of heterogeneous variance on the conclusions 
for repeated-measures analyses. Fifth, the analyses only 
addressed the frequency of medication-taking, not the timing 
of medication-taking. Sixth, ASM analyses can require exten-
sive computation time. Finally, ASM methods currently are 
not directly supported by statistical software tools.   However, 
they have been implemented in SAS macros available from 
the corresponding author.
Conclusion
Over the past 30 years, numerous interventions have been 
developed to improve medication adherence in hypertensive 
patients; however, no single strategy has emerged as superior 
for all patients.23 While complex intervention strategies have 
proven more successful than simple strategies,24 they too 
have failed to demonstrate sizable effects that justify the high 
costs and resources needed for implementation.25 Rather than 
developing more complex, resource-intensive interventions, 
new innovative methods are needed that directly address the 
multifaceted nature of patient medication-taking behaviors. 
ASM methods provide an approach for developing tailored 
and potentially cost-effective intervention strategies to 
improve adherence in patients who are at greatest risk for 
poor adherence, such as those with lower socioeconomic 
status and who are in racial/ethnic minorities.26
The findings of this study have several important implica-
tions that can guide future intervention efforts. First, exam-
ining individual adherence patterns can assist in developing 
patient-specific intervention strategies that could maximize 
efforts to improve patient’s medication-taking behaviors. For 
example, patients who are nonadherent due to self-termination 
of their medication require counseling approaches that build 
confidence and motivation to continue with treatment, even 
in situations that may pose   challenging. Alternatively, patients 
whose nonadherence is due to problems with execution of the 
regimen require counseling approaches that assist in develop-
ing behavioral action plans and identifying sources of social 
support to assist in taking medications as prescribed.
ASM methods could also be applied to future clinical trials 
by the inclusion of a run-in phase during the first month of the 
trial to generate adherence types and stratify patients accord-
ing to their adherence status as well as other key psychosocial 
and clinical characteristics. This initial groundwork could help 
researchers to determine which intervention approach would be 
best matched to individual patient needs and to facilitate medi-
cation adherence behaviors. It is crucial that this   preliminary 
assessment be made close to randomization into treatment groups 
because it is not clear whether a patient’s long-term history of 
medication taking is as good an indicator of that patient’s pres-
ent or future medication-taking behavior. For example, patients 
may have been consistently adherent until a future significant 
life event/stressor occurs and interferes with medication-taking 
behavior, after which their adherence   deteriorates. These kinds 
of events may be the root cause for some deteriorating individual 
patient adherence patterns. Research is needed on what length of 
a run-in period would be most effective for predicting subsequent 
medication-taking behavior.
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